Clicky

biOasis Technologies Inc.(BTI)

Description: biOasis Technologies Inc. is a development-stage biopharmaceutical company, which is focused on research, development and commercialization of technologies and products that are intended for the treatment of central nervous system (CNS) diseases and diseases of the brain. The Company researches and develops products for diagnosis and treatment of neurological diseases and disorders. It is engaged in the development of its vectors Transcend and Transcendpep for the transport of therapeutic agents across the blood brain barrier (BBB). The Transcend brain delivery platform exploits the BBB penetrating properties of a recombinant soluble human protein known as melanotransferrin (MTf or p97) and portions thereof. Transcend delivery molecules have the ability to transport a range of molecules across the BBB. The Company owns approximately 30 the United States and foreign patents/applications related to p97 as a BBB delivery vector and as a biomarker for Alzheimer's disease.


Keywords: Medicine Transport Pharmaceutical Biopharmaceutical Biology Disease Alzheimer's Disease Disorders Pharma Neurology Pharmacokinetics Nervous System Neurological Diseases Animal Physiology Brain Central Nervous System Blood–Brain Barrier Treatment Of Neurological Diseases

Home Page: www.bioasis.us

BTI Technical Analysis

157 Church Street
New Haven, CT 06510
United States
Phone: 203 533 7082


Officers

Name Title
Dr. Deborah Ann Rathjen B.Sc. (Hons.), FTSE, M.A.I.C.D., Ph.D., Q.C. Exec. Chairman, CEO & Pres
Mr. Dave Jenkins Chief Financial Officer
Mr. Graeme Dick Director of Investor Relations
Mr. Kim Elton Director of Marketing
Mr. Doug Williams MBA Exec. VP & Chief Bus. Officer
Dr. Mei Mei Tian VP & Head of External Research

Exchange: V

Country: CA

Currency: Canadian Dollar (C$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 54.0377
Price-to-Sales TTM: 35.1467
IPO Date:
Fiscal Year End: February
Full Time Employees: 0
Back to stocks